Amy Lam PhD

Associate Director - Consulting & IP Transactions

Symbiosis IP

Expertise

Amy has over 20 years’ experience working with IP and advising on technology commercialisation, having held a variety of roles focused on IP valuation, partnering and technology licensing. An IP and commercialisation consultant for the past 8 years, Amy led and conducted over 120 life science consulting projects for public and private sector clients from around the world covering innovations in areas such as genome editing, cell therapy, small molecule therapeutics and medical diagnostics. In addition, Amy has also undertaken numerous IP valuations for clients across diverse industries, including pharmaceuticals, medical devices, oil and gas, and SaaS sectors. 

Amy graduated with a first-class honours degree in Pharmacology & Toxicology from the School of Pharmacy, UCL, University of London, and was awarded her PhD in Neuroscience from the University of Glasgow. Amy also holds an MSc in IP Law from Queen Mary University. 

Amy has a client-focused outlook in her approach and has worked in both academia and industry in the UK and the USA. Prior to joining Gateley, previous in-house roles included Head of Business Development for the College of Medicine at the University of Edinburgh, and IP Licensing Manager for a life sciences contract research organisation.

How do you help clients? 

I help clients realise additional value from their intellectual property, whether that be direct hands-on support to identify and find suitable commercialisation and licensing partners, advising and negotiating commercial and IP terms in a deal, or advising clients on their IP management strategy to enable them to capture, protect and work their IP more effectively.

I also advise clients with intellectual property valuations. For example, I have undertaken valuations for companies wishing to raise their next round of investment; to help inform internal investment decision-making through the identification of key risks and assumptions and assessment of the scope of the opportunity; and for royalty buy-out purposes.

With respect to IP licensing, my experience from working across both academic and commercial environments allows me contextualise deal terms that may be unfamiliar to clients and offer clients clear insights on how to best navigate these in order achieve their objectives. This experience has also allowed me to provide longer-term retained operational and management functions to both technology transfer functions within universities and contracting and IP functions within SMEs.

Experience

  1. Valuation of future royalty streams for a number of cancer therapeutics to help determine the potential value to support a possible sale of part or all of future royalties to royalty monetisation companies.
  2. Advised a corporate client and its Board of Directors on the competitive positioning of its products against its global competitors and growth opportunities.
  3. Provided retained part-time support to the technology transfer function within the commercialisation office for a leading Russell group university for five years.
  4. Provided interim contract management support for a young biotech for over six months. 
  5. Provided advice to clients to help them align their IP strategy with the commercial goals of the business.